

DAFTAR PUSTAKA

- Aartsma-Rus, A. *et al.* (2006) 'Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.', *Muscle & nerve*, 34(2), pp. 135–44. doi: 10.1002/mus.20586.
- Arbustini, E. *et al.* (2000) 'Prevalence and Characteristics of Dystrophin Defects in Adult Male Patients With Dilated Cardiomyopathy', 35(7), pp. 5–8. doi: 10.1016/S0735-1097(00)00650-1.
- Bell, C. D. and Conen, P. E. (1968) 'Histopathological changes in Duchenne muscular dystrophy', *Journal of the Neurological Sciences*, 7(3), pp. 529–544. doi: 10.1016/0022-510X(68)90058-0.
- Bladen, C. L. *et al.* (2015) 'The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations', *Human Mutation*, 36(4), pp. 395–402. doi: 10.1002/humu.22758.
- Blake, D. J. *et al.* (2002) 'Function and genetics of dystrophin and dystrophin-related proteins in muscle.', *Physiological reviews*, 82(2), pp. 291–329. doi: 10.1152/physrev.00028.2001.
- Bonilla, E. *et al.* (1988) 'Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface', *Cell*, 54(4), pp. 447–452. doi: 10.1016/0092-8674(88)90065-7.
- Bushby, K. *et al.* (2010) 'Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management', *The Lancet Neurology*, 9(1), pp. 77–93. doi: 10.1016/S1474-4422(09)70271-6.
- Chan, S. H. S. *et al.* (2015) 'Prevalence and Characteristics of Chinese Patients With Duchenne and Becker Muscular Dystrophy', *Child Neurology Open*, 2(2), p. 2329048X1558534. doi: 10.1177/2329048x15585345.
- Clerk, A. *et al.* (1991) 'Characterisation of dystrophin in carriers of Duchenne muscular dystrophy', *Journal of the Neurological Sciences*, 102(2), pp. 197–205. doi: 10.1016/0022-510X(91)90069-J.
- Crauciuc, G. A. *et al.* (2018) 'Multiplex ligation dependent probe amplification - A useful, fast and cost-effective method for identification of small supernumerary marker chromosome in children with developmental delay and congenital heart defect', *Revista Romana de Medicina de Laborator*, 26(4), pp. 461–470. doi: 10.2478/rrlm-2018-0032.
- Crisafulli, S. *et al.* (2020) 'Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis', *Orphanet Journal of Rare Diseases*, 15(1). doi: 10.1186/s13023-020-01430-8.
- Dooley, J. *et al.* (2010) 'Duchenne muscular dystrophy: A 30-year population-based incidence study', *Clinical Pediatrics*, 49(2), pp. 177–179. doi: 10.1177/0009922809347777.
- Echigoya, Y. *et al.* (2013) 'Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice', *PLoS ONE*, 8(7). doi: 10.1371/journal.pone.0069194.
- Emery, A. E. H. (1991) 'Population frequencies of inherited neuromuscular

- diseases-A world survey', *Neuromuscular Disorders*, 1(1), pp. 19–29. doi: 10.1016/0960-8966(91)90039-U.
- Freund, A. A. *et al.* (2007) 'Duchenne and Becker muscular dystrophy: A molecular and immunohistochemical approach', *Arquivos de Neuro-Psiquiatria*, 65(1), pp. 73–76. doi: 10.1590/S0004-282X2007000100016.
- Giliberto, F. *et al.* (2014) 'Symptomatic female carriers of Duchenne muscular dystrophy (DMD): Genetic and clinical characterization', *Journal of the Neurological Sciences*, 336(1–2), pp. 36–41. doi: 10.1016/j.jns.2013.09.036.
- Gown, A. M. (2016) 'Diagnostic immunohistochemistry: What can go wrong and how to prevent it', *Archives of Pathology and Laboratory Medicine*, 140(9), pp. 893–898. doi: 10.5858/arpa.2016-0119-RA.
- Grunau, G. and Linn, S. (2018) 'Commentary: Sensitivity, Specificity, and Predictive Values: Foundations, Plabilities, and Pitfalls in Research and Practice', *Frontiers in Public Health*, 6(September), pp. 1–4. doi: 10.3389/fpubh.2018.00256.
- Hoshino, S. *et al.* (2000) 'Immunohistochemical staining of dystrophin on formalin-fixed paraffin-embedded sections in Duchenne/Becker muscular dystrophy and manifesting carriers of Duchenne muscular dystrophy', *Neuromuscular Disorders*, 10(6), pp. 425–429. doi: 10.1016/S0960-8966(99)00116-9.
- Iskandar, K. *et al.* (2019) 'The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: The era of personalized medicine', *BMC Research Notes*, 12(1), pp. 1–6. doi: 10.1186/s13104-019-4730-1.
- Janssen, B. *et al.* (2005) 'MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: Potential and pitfalls', *Neurogenetics*, 6(1), pp. 29–35. doi: 10.1007/s10048-004-0204-1.
- Kharraz, Y. *et al.* (2014) 'Understanding the process of fibrosis in duchenne muscular dystrophy', *BioMed Research International*, 2014. doi: 10.1155/2014/965631.
- Lai, K. K. S. *et al.* (2006) 'Detecting exon deletions and duplications of the DMD gene using Multiplex Ligation-dependent Probe Amplification (MLPA)', *Clinical Biochemistry*, 39(4), pp. 367–372. doi: 10.1016/j.clinbiochem.2005.11.019.
- Lai, P. S. *et al.* (2002) 'Comparative study on deletions of the dystrophin gene in three asian populations', *Journal of Human Genetics*, 47(10), pp. 552–555. doi: 10.1007/s100380200084.
- Laing, N. G. *et al.* (2011) 'Molecular diagnosis of duchenne muscular dystrophy: Past, present and future in relation to implementing therapies', *Clinical Biochemist Reviews*, 32(3), pp. 129–134.
- Lalic, T. *et al.* (2005) 'Deletion and duplication screening in the DMD gene using MLPA', *European Journal of Human Genetics*, 13(11), pp. 1231–1234. doi: 10.1038/sj.ejhg.5201465.
- Leigh, F. *et al.* (2018) 'Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophy', *Pediatrics*, 142(October 2018), pp. S5–S16. doi: 10.1542/peds.2018-0333C.

- Li, W. *et al.* (2015) 'Progression and variation of fatty infiltration of the thigh muscles in Duchenne muscular dystrophy, a muscle magnetic resonance imaging study', *Neuromuscular Disorders*, 25(5), pp. 375–380. doi: 10.1016/j.nmd.2015.01.003.
- Lobo-Prat, J. *et al.* (2016) 'Implementation of EMG-and force-based control interfaces in active elbow supports for men with duchenne muscular dystrophy: a feasibility study', *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, 24(11), pp. 1179–1190. doi: 10.1109/TNSRE.2016.2530762.
- Mah, J. K. *et al.* (2014) 'A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy', *Neuromuscular Disorders*, 24(6), pp. 482–491. doi: 10.1016/j.nmd.2014.03.008.
- Malfatti, E. and Romero, N. (2017) *Diseases of the skeletal muscle. Handbook of Clinical Neurology*. Amsterdam: Elsevier B.V.
- Manjunath, M. *et al.* (2015) 'A comparative study of mPCR, MLPA, and muscle biopsy results in a cohort of children with Duchenne muscular dystrophy: A first study', *Neurology India*, 63(1), pp. 58–62. doi: 10.4103/0028-3886.152635.
- Manzur, A. Y. *et al.* (1992) 'A Randomized Controlled Trial of Early Surgery in Duchene Muscular Dystrophy', *Pergamon Press Ltd*, 2(516), pp. 379–387.
- McMillan, H. J. *et al.* (2011) 'Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy', *Pediatrics*, 127(1). doi: 10.1542/peds.2010-0929.
- Mendell, J. R. *et al.* (2012) 'Evidence-based path to newborn screening for duchenne muscular dystrophy', *Annals of Neurology*, 71(3), pp. 304–313. doi: 10.1002/ana.23528.
- Muntoni, F., Torelli, S. and Ferlini, A. (2003) 'Dystrophin and mutations: One gene, several proteins, multiple phenotypes', *Lancet Neurology*, 2(12), pp. 731–740. doi: 10.1016/S1474-4422(03)00585-4.
- Nadifi, S. *et al.* (2009) 'Duchenne and becker muscular dystrophy: Contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco', *Journal of Biomedicine and Biotechnology*, 2009. doi: 10.1155/2009/325210.
- Nadkarni, J. *et al.* (2008) 'Becker muscular dystrophy in Indian patients: Analysis of dystrophin gene deletion patterns', *Neurology India*, 56(3), p. 374. doi: 10.4103/0028-3886.40961.
- Nakamura, A. *et al.* (2008) 'Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene', *Journal of Clinical Neuroscience*, 15(7), pp. 757–763. doi: 10.1016/j.jocn.2006.12.012.
- Nishida, A. *et al.* (2011) 'Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.', *Nature communications*, 2(1), p. 308. doi: 10.1038/ncomms1306.
- Nowak, K. J. and Davies, K. E. (2004) 'Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment', 5(9). doi:

- 10.1038/sj.embor.7400221.
- Parsons, E. P., Clarke, A. J. and Bradley, D. M. (2004) 'Developmental progress in Duchenne muscular dystrophy: Lessons for earlier detection', *European Journal of Paediatric Neurology*, 8(3), pp. 145–153. doi: 10.1016/j.ejpn.2004.01.009.
- Pascal, L. E. *et al.* (2008) 'Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate', *BMC Genomics*, 9, pp. 1–13. doi: 10.1186/1471-2164-9-246.
- Passamano, L. *et al.* (2012) 'Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients', *Acta Myologica*, 31(OCTOBER), pp. 121–125.
- Sajid, S. *et al.* (2011) 'Muscular Dystrophies and the Role of Dystrophin in Their Diagnosis', 27, pp. 33–38.
- Sakthivel Murugan, S. M., Chandramohan, A. and Lakshmi, B. R. (2010) 'Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis', *Indian Journal of Medical Research*, 132(9), pp. 303–311.
- Sansovic, I., Baris'ic', I. and Domic, K. (2012) 'Improved Detection of Deletions and Duplications in the DMD Gene Using the Multiplex Ligation-Dependent Probe Amplification (MLPA) Method'. New York: Springer Science. doi: Sansovic, I., Baris'ic', I., & Domic, K., n.d. Improved Detection of Deletions and Duplications in the DMD Gene Using the Multiplex Ligation-Dependent Probe Amplification (MLPA) Method.
- Schwartz, M. and Dunø, M. (2004) *Improved Molecular Diagnosis of Dystrophin Gene Mutations Using the Multiplex Ligation-Dependent Probe Amplification Method*, *Genetic testing*.
- Sheriffs, I. N., Rampling, D. and Smith, V. V. (2001) 'Paraffin wax embedded muscle is suitable for the diagnosis of muscular dystrophy', *Journal of Clinical Pathology*, 54(7), pp. 517–520. doi: 10.1136/jcp.54.7.517.
- Shin, J. *et al.* (2013) 'Wasting mechanisms in muscular dystrophy', *International Journal of Biochemistry and Cell Biology*, 45(10), pp. 2266–2279. doi: 10.1016/j.biocel.2013.05.001.
- Strehle, E. M. and Straub, V. (2015) 'Recent advances in the management of Duchenne muscular dystrophy', *Archives of Disease in Childhood*, 100(12), pp. 1173–1177. doi: 10.1136/archdischild-2014-307962.
- Suriyonplengsaeng, C. *et al.* (2017) 'Immunohistochemistry of sarcolemmal membrane-associated proteins in formalin-fixed and paraffin-embedded skeletal muscle tissue: A promising tool for the diagnostic evaluation of common muscular dystrophies', *Diagnostic Pathology*, 12(1), pp. 1–10. doi: 10.1186/s13000-017-0610-y.
- Todorova, A. *et al.* (2008) 'MLPA analysis/complete sequencing of the DMD gene in a group of Bulgarian Duchenne/Becker muscular dystrophy patients', *Neuromuscular Disorders*, 18(8), pp. 667–670. doi: 10.1016/j.nmd.2008.06.369.
- Tokarz, S. A. *et al.* (1998) 'Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of

- duchenne muscular dystrophy', *Molecular Genetics and Metabolism*, 65(4), pp. 272–281. doi: 10.1006/mgme.1998.2763.
- Tomar, S. *et al.* (2019) 'Mutational spectrum of dystrophinopathies in Singapore: Insights for genetic diagnosis and precision therapy', *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, 181(2), pp. 230–244. doi: 10.1002/ajmg.c.31704.
- True, L. D. (2008) 'Quality control in molecular immunohistochemistry', *Histochemistry and Cell Biology*, 130(3), pp. 473–480. doi: 10.1007/s00418-008-0481-0.
- Vogel, H. and Zamecnik, J. (2005) 'Diagnostic immunohistology of muscle diseases', *Journal of Neuropathology and Experimental Neurology*, 64(3), pp. 181–193. doi: 10.1093/jnen/64.3.181.
- Wang, D.-N. *et al.* (2017) 'Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.', *Neuromuscular disorders: NMD*, 27(8), pp. 715–722. doi: 10.1016/j.nmd.2017.02.010.
- Werneck, L. C. *et al.* (2001) 'Comparative Analysis of PCR-Deletion Detection and Immunohistochemistry in Brazilian Duchenne and Becker Muscular Dystrophy Patients', 120, pp. 115–120.
- Wong, H. B. and Lim, G. H. (2011) 'Measures of diagnostic accuracy: Sensitivity, specificity, PPV and NPV', *Proceedings of Singapore Healthcare*, 20(4), pp. 316–318. doi: 10.1177/201010581102000411.
- Yang, J. *et al.* (2013) 'MLPA-based genotype-phenotype analysis in 1053 Chinese patients with DMD/BMD.', *BMC medical genetics*, 14. doi: 10.1186/1471-2350-14-29.